Journal
EUROPEAN JOURNAL OF CANCER
Volume 36, Issue 5, Pages 675-681Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0959-8049(99)00335-4
Keywords
TGF-beta receptor; endoglin; tumour neovasculature; angiogenesis; imaging
Categories
Funding
- NCI NIH HHS [2-RO1 CA 59649-05] Funding Source: Medline
Ask authors/readers for more resources
In vivo imaging of endothelial markers in intact tumour neovasculature would have applications in assessing the efficacy of antiangiogenic agents in clinical trials. Although a variety of different endothelial markers have been described, few have been evaluated as imaging markers. The transforming growth factor-beta (TGF-beta) binding receptor endoglin is a proliferation-associated endothelial marker. We hypothesised that endoglin would be an ideal target for imaging since it is strongly upregulated in proliferating endothelial cells of the tumour neovasculature. We used a radiolabelled monoclonal anti-endoglin antibody and compared its neovascular binding, accumulation and in vivo behaviour to an isotype-matched control IgG(2a). Our data show that the probe binds specifically and rapidly within minutes in vivo and that correlative autoradiography and immunohistology support the in vivo imaging findings. Imaging of abundantly expressed endothelial targets circumvents delivery barriers normally associated with other tumour targeting strategies, and can potentially be used to quantitate molecular angiogenic markers. (C) 2000 Elsevier Science Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available